COMPARATIVE ANALYSIS OF LONG-ACTING INSULINS: INSULIN DEGLUDEC VS. NPH INSULIN IN TYPE 1 DIABETES

Abstract

Type 1 diabetes mellitus (T1DM) is a condition characterized by the autoimmune or idiopathic destruction of pancreatic ß-cells, resulting in insulin deficiency. To manage T1DM, patients require insulin replacement therapy, with basal-bolus insulin injection being the mainstay of treatment. While Neutral Protamine Hagedorn (NPH) insulin is an intermediate-acting insulin commonly used as basal insulin, insulin glargine, a long-acting insulin analog, has proven to be more effective as a basal insulin compared to NPH insulin. As a result, long-acting insulin is now the preferred choice for basal insulin in basal-bolus insulin therapy. However, even with the use of long-acting insulin, blood glucose control remains suboptimal.

This study aims to address the issue of suboptimal blood glucose control in T1DM patients by exploring alternative insulin therapies. The effectiveness of long-acting insulin analogs will be evaluated in comparison to NPH insulin, and their impact on blood glucose management will be assessed.